The COVID-19 pandemic caused by SARS-Cov-2 demands rapid, safe and effective therapeutic options. In the last decades, the endogenous gasotransmitter hydrogen sulfide (H2S) has emerged as modulator of several biological functions and its deficiency has been associated with different disorders. Therefore, many H2S-releasing agents have been developed as potential therapeutic tools for diseases related with impaired H2S production and/or activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of H2S in modulating the inflammatory response and pro-inflammatory cytokine cascade is well recognized, and the usefulness of some H2S-donors for the treatment of acute lung inflammation has been reported. Recent data is elucidating several mechanisms of action, which may account for antiviral effects of H2S. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous H2S levels and severity of COVID-19. Therefore, repurposing of H2S-releasing drugs may be a potential therapeutic opportunity for treatment of COVID-19.

Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2S donors in COVID-19 therapy

Citi V.;Martelli A.
;
Brogi S.;Testai L.;Calderone V.
2020

Abstract

The COVID-19 pandemic caused by SARS-Cov-2 demands rapid, safe and effective therapeutic options. In the last decades, the endogenous gasotransmitter hydrogen sulfide (H2S) has emerged as modulator of several biological functions and its deficiency has been associated with different disorders. Therefore, many H2S-releasing agents have been developed as potential therapeutic tools for diseases related with impaired H2S production and/or activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of H2S in modulating the inflammatory response and pro-inflammatory cytokine cascade is well recognized, and the usefulness of some H2S-donors for the treatment of acute lung inflammation has been reported. Recent data is elucidating several mechanisms of action, which may account for antiviral effects of H2S. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous H2S levels and severity of COVID-19. Therefore, repurposing of H2S-releasing drugs may be a potential therapeutic opportunity for treatment of COVID-19.
Citi, V.; Martelli, A.; Brancaleone, V.; Brogi, S.; Gojon, G.; Montanaro, R.; Morales, G.; Testai, L.; Calderone, V.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11568/1052011
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 27
social impact